Related Experiment Video
Updated: Jan 10, 2026

05:07
Author Spotlight: Improved Localization and Monitoring of Coronary Flow Reserve Using Modified PLAX View in Mice
Published on: August 25, 2023
1.8K
No-Reflow During Coronary Interventions: A Narrative Review.
Sara Malakouti1,2, Ahmed Hashim1,3, Marco Frazzetto1,4
1DCB Academy, 20136 Milano, Italy.
Journal of Clinical Medicine
|November 27, 2025
Summary
The coronary no-reflow phenomenon, a complication of cardiac procedures, hinders microvascular perfusion and worsens patient outcomes. This review integrates pathophysiology, diagnostics, and therapies, proposing AI-driven solutions for better treatment.
Area of Science:
- Cardiology
- Interventional Cardiology
- Cardiovascular Research
Background:
- The coronary no-reflow phenomenon is a significant complication during percutaneous coronary interventions, particularly in acute coronary syndrome.
- Despite restoring epicardial artery flow, impaired microvascular perfusion leads to adverse events like heart failure and increased mortality.
- Current understanding of multifactorial pathophysiology and therapeutic strategies remains incomplete.
Purpose of the Study:
- To provide an integrated perspective on the multifactorial pathophysiology of coronary no-reflow.
- To review advances in diagnostic imaging and therapeutic options for managing this condition.
- To explore future directions, including AI-based predictive modeling and targeted microvascular treatments.
Main Methods:
- Comprehensive literature review integrating pathophysiology, diagnostic imaging, and therapeutic interventions.
- Analysis of systemic inflammation, thrombogenicity, ischemia-reperfusion injury, and distal embolization.
- Evaluation of current and emerging treatments, including antithrombotics, vasodilators, and mechanical adjuncts.
Main Results:
- No-reflow involves complex interactions of inflammation, clotting, reperfusion injury, and embolization.
- Advanced imaging like cardiac MRI and CT aids in diagnosis and understanding.
- Existing therapies show limitations, highlighting unmet clinical needs.
Conclusions:
- Personalized treatment approaches are crucial for improving outcomes in patients with coronary no-reflow.
- Future research should focus on AI for predictive modeling and novel microvascular therapies.
- Addressing no-reflow is essential for reducing mortality and improving long-term cardiovascular health.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
Coronary Artery Disease V: Interprofessional Care
206
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
206

